Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial - Nature Communications Advanced HIV-1 infection is associated with gut dysbiosis, and it’s not known whether this is reversed with antiviral therapy. The ADVANZ-4 MISTRAL trial shows that dolutegravir restores gut microbiota in late-stage HIV1 patients better than darunavir, and that recovery is linked to improved immune reconstitution.

Clinical trial: dolutegravir restores gut microbiota in late-stage HIV-1 patients better than darunavir, linked to improved immune reconstitution

@rutgerwalls.bsky.social @fcatalamoll.bsky.social @irsicaixa.es @hospitalclinic.bsky.social

#naturecommunications | Roger Paredes Today we publish in #NatureCommunications evidence that dolutegravir, unlike darunavir, helps restore the gut microbiome in people presenting late with HIV In our multicentre, open‑label RCT (96 week...

www.linkedin.com/posts/roger-...

Beyond Viral Suppression: How the Right HIV Drug Helps the Gut Heal Itself Can specific HIV drugs heal the gut? For late-stage patients, viral suppression isn't enough to stop chronic inflammation. Our 2-year trial reveals that dolutegravir, unlike darunavir, profoundly restores the gut microbiome, offering a new pathway to long-term health and reduced inflammation.

Beyond Viral Suppression: How the Right #HIV Drug Helps the Gut Heal Itself

@rutgerwalls.bsky.social @fcatalamoll.bsky.social @irsicaixa.es @hospitalclinic.bsky.social
#Microbiome

Day 2 of #adventofcode with #rstats. Trying to recycle functions

it's #adventofcode time! here's my #rstats solution to day 1